Laura Hummers
Elite in Systemic Sclerosis (SSc)

Dr. Laura Hummers

Rheumatology
Johns Hopkins Medicine
Johns Hopkins Bayview Medical Center
5501 Hopkins Bayview Circle, Floor 1, Floor 1, 
Baltimore, MD 

Elite in Systemic Sclerosis (SSc)
Johns Hopkins Medicine
Johns Hopkins Bayview Medical Center
5501 Hopkins Bayview Circle, Floor 1, Floor 1, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Hummers is an Associate Professor of Medicine in the Division of Rheumatology. She graduated from the University of Rochester School of Medicine and trained in internal medicine at Thomas Jefferson University. She then pursued her rheumatology fellowship at Johns Hopkins University and has since been on the faculty working at the Johns Hopkins Scleroderma Center since 2003 where she has been Co-Director of the Center. She received her ScM degree through the Graduate Training Program in Clinical Investigation from the Bloomberg School of Public Health in 2010. Dr. Hummers also serves as Clinical Director for the Division of Rheumatology. Dr. Hummers actively participates in a number of clinical trials and clinical investigations at the Scleroderma Center and has a particular interest in predictors of outcomes in scleroderma. She actively manages a large patient practice focused exclusively on scleroderma and related conditions at Johns Hopkins and actively helps to manage the Johns Hopkins Scleroderma Center longitudinal database. She also has specific expertise in other scleroderma-like conditions such as scleromyxedema, scleredema and eosinophilic fasciitis.

Dr. Hummers is rated as an Elite provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Eosinophilic Fasciitis, and Scleroma.

Her clinical research consists of co-authoring 138 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 122 articles and participated in 7 clinical trials in the study of Systemic Sclerosis (SSc).

Graduate Institution
Johns Hopkins Bloomberg School Of Public Health, ScM, 2010
Residency
Thomas Jefferson University Hospitals, Internal Medicine, 2000
Specialties
Rheumatology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine, Rheumatology, 2003
Hospital Affiliations
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northwell Health
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Johns Hopkins Bayview Medical Center
5501 Hopkins Bayview Circle, Floor 1, Floor 1, Baltimore, MD 21224
Call: 443-997-1552

Additional Areas of Focus

Dr. Hummers has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Scleroderma
Scleromyxedema

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Other
Study Drug: Tepezza Anti-IGF-1 Receptor Monoclonal Antibody
Study Phase: Phase 1
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Biological
Study Drug: Brentuximab vedotin
Study Phase: Phase 1/Phase 2
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drugs: Pirfenidone, Mycophenolate Mofetil
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis
Enrollment Status: Unknown
Publish Date: July 17, 2018
Intervention Type: Biological
Study Phase: Not Applicable
View 6 Less Clinical Trials

138 Total Publications

Type III and type VI collagen neoepitopes are associated with disease severity in systemic sclerosis.
Type III and type VI collagen neoepitopes are associated with disease severity in systemic sclerosis.
Journal: The Journal of rheumatology
Published: November 15, 2025
View All 138 Publications
Similar Doctors
Fredrick Wigley
Elite in Systemic Sclerosis (SSc)
Dr. Fredrick Wigley
Rheumatology
Elite in Systemic Sclerosis (SSc)
Dr. Fredrick Wigley
Rheumatology

Johns Hopkins Bayview Medical Center

Baltimore, MD 
 (0.1 miles away)
443-997-1552
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Wigley received his M.D. degree from the University of Florida College of Medicine. He completed an internship and residency at Johns Hopkins where he also trained in a postdoctoral fellowship program. Dr. Wigley is a physician-scientist whose specialty is Raynaud’s phenomenon and scleroderma. He founded The Johns Hopkins Scleroderma Center with Robert A. Wise, M.D., of the Johns Hopkins Division of Pulmonary Medicine. Dr. Wigley has been honored with two American College of Rheumatology awards over the past couple years. He received the ACR Distinguished Clinician Scholar Award in 2009 and the ACR Masters Award in 2011. Dr. Wigley is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Raynaud Phenomenon, and Scleroma.

Elite in Systemic Sclerosis (SSc)
Dr. Virginia D. Steen
Rheumatology | Allergy and Immunology
Elite in Systemic Sclerosis (SSc)
Dr. Virginia D. Steen
Rheumatology | Allergy and Immunology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (38.5 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Virginia Steen is a Rheumatologist and an Allergy and Immunologist in Washington, Washington, D.c.. Dr. Steen is rated as an Elite provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Kuru, and Scleroma.

Julie Paik
Elite in Systemic Sclerosis (SSc)
Dr. Julie Paik
Rheumatology
Elite in Systemic Sclerosis (SSc)
Dr. Julie Paik
Rheumatology

Johns Hopkins Bayview Medical Center

Baltimore, MD 
 (0.1 miles away)
443-997-1552
Languages Spoken:
English, Korean
See accepted insurances

Dr. Julie Paik completed her medical school training at the George Washington University School of Medicine in Washington, DC. She then completed her residency and chief residency at UCLA-Cedars-Sinai/VA Medical Center in Los Angeles, California. She completed rheumatology fellowship at Johns Hopkins and joined the faculty in 2013. She currently sees patients at the Johns Hopkins Myositis Center and Scleroderma Center. Her research interests are in myositis and scleroderma or overlap myositis. She also has a special interest in novel therapeutics in refractory dermatomyositis. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Paik is rated as an Elite provider by MediFind in the treatment of Systemic Sclerosis (SSc). Her top areas of expertise are Dermatomyositis, Polymyositis, Myositis, and Scleroderma.

VIEW MORE SYSTEMIC SCLEROSIS (SSC) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hummers's expertise for a condition
ConditionClose
  • Elite
  • Scleroderma
    Dr. Hummers is
    Elite
    . Learn about Scleroderma.
    See more Scleroderma experts
  • Systemic Sclerosis (SSc)
    Dr. Hummers is
    Elite
    . Learn about Systemic Sclerosis (SSc).
    See more Systemic Sclerosis (SSc) experts
  • Distinguished
  • Eosinophilic Fasciitis
    Dr. Hummers is
    Distinguished
    . Learn about Eosinophilic Fasciitis.
    See more Eosinophilic Fasciitis experts
  • Raynaud Phenomenon
    Dr. Hummers is
    Distinguished
    . Learn about Raynaud Phenomenon.
    See more Raynaud Phenomenon experts
  • Scleroma
    Dr. Hummers is
    Distinguished
    . Learn about Scleroma.
    See more Scleroma experts
  • Advanced
  • Localized Scleroderma
    Dr. Hummers is
    Advanced
    . Learn about Localized Scleroderma.
    See more Localized Scleroderma experts
  • Myositis
    Dr. Hummers is
    Advanced
    . Learn about Myositis.
    See more Myositis experts
  • Scleredema
    Dr. Hummers is
    Advanced
    . Learn about Scleredema.
    See more Scleredema experts
  • Experienced
  • Antisynthetase Syndrome
    Dr. Hummers is
    Experienced
    . Learn about Antisynthetase Syndrome.
    See more Antisynthetase Syndrome experts
  • Arthritis
    Dr. Hummers is
    Experienced
    . Learn about Arthritis.
    See more Arthritis experts
  • Dermatomyositis
    Dr. Hummers is
    Experienced
    . Learn about Dermatomyositis.
    See more Dermatomyositis experts
  • Eosinophilia-Myalgia Syndrome
    Dr. Hummers is
    Experienced
    . Learn about Eosinophilia-Myalgia Syndrome.
    See more Eosinophilia-Myalgia Syndrome experts
  • Erythema Nodosum
    Dr. Hummers is
    Experienced
    . Learn about Erythema Nodosum.
    See more Erythema Nodosum experts
  • Granulomatosis with Polyangiitis
    Dr. Hummers is
    Experienced
    . Learn about Granulomatosis with Polyangiitis.
    See more Granulomatosis with Polyangiitis experts
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.